Clinical Trial Update: UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Autoimmune Hemolytic Anemia [EARLY_Phase 1]

View source ↗

Summary

An early-phase (Phase 1) UCAR T-cell therapy targeting CD19 and BCMA is being investigated for relapsed or refractory Autoimmune Hemolytic Anemia, with the tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia

Drugs mentioned

• UCAR T-cell therapy targeting CD19/BCMA

Snippet

Sponsor: Zhejiang University | Conditions: Relapsed / Refractory Autoimmune Hemolytic Anemia | EARLY_Phase 1 | Status: NOT_YET_RECRUITING